Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide.

摘要: In this phase I/II study, we evaluated the feasibility, safety and efficacy of allogeneic dendritic cells (DCs) with or without cyclophosphamide in treatment patients metastatic renal cell carcinoma (RCC). Immunomagnetic beads were used to isolate CD14(+) monocytes from healthy donor leukapheresis products, CD83(+) antigen-pulsed monocyte-derived DCs (moDCs) loaded tumor lysate keyhole limpet hemocyanin (KLH) generated. Twelve treated moDCs alone, while ten also received on days 4 3 prior vaccination. Of 22 enrolled, 20 full consisting at least three vaccinations monthly intervals. Two mixed responses substantial regression observed. patients, disease stabilization occurred, 13 progressed lost follow-up. Overall, immune against KLH weak absent; however, strongest increases antigen-independent KLH-specific observed 2 responses. addition, 1 them showed a increase oncofetal antigen (OFA)-specific IFN-gamma production. Importantly, responders patient stable belonged group. Median overall survival group was 23.2 20.3 months that alone. Allogeneic immunotherapy is feasible well tolerated. However, immunogenicity clearly less pronounced than autologous moDC immunotherapy. Cyclophosphamide may have capacity augment DC-induced antitumor immunity.